(Q39974009)

16 September 2017

title

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule (English)

1 reference

16 September 2017

6

1 reference

16 September 2017

Helene Andersson-Svahn

4

object named as

Helene Andersson-Svahn

0 references

Fredrik Y Frejd

8

object named as

Fredrik Y Frejd

1 reference

16 September 2017

Mikaela Friedman

1

1 reference

16 September 2017

Sara Lindström

2

1 reference

16 September 2017

Lina Ekerljung

3

1 reference

16 September 2017

Helene Andersson-Svahn

4

1 reference

16 September 2017

Jörgen Carlsson

5

1 reference

16 September 2017

Lars Gedda

7

1 reference

16 September 2017

Stefan Ståhl

9

1 reference

16 September 2017

publication date

21 August 2009

1 reference

Biotechnology and Applied Biochemistry

16 September 2017

published in

1 reference

16 September 2017

volume

54

1 reference

16 September 2017

issue

2

1 reference

16 September 2017

page(s)

121-131

1 reference

Recombinant approaches to IgG-like bispecific antibodies

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Recombinant bispecific antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Bispecific antibody conjugates in therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

A synthetic IgG-binding domain based on staphylococcal protein A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Affibody molecules in protein capture microarrays: evaluation of multidomain ligands and different detection formats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Mammalian cell production of a respiratory syncytial virus (RSV) candidate vaccine recovered using a product-specific affinity column

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Affibody-mediated transferrin depletion for proteomics applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Tumor imaging using a picomolar affinity HER2 binding affibody molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Binding proteins from alternative scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Construction and characterization of affibody-Fc chimeras produced in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Generation of Affibody ligands binding interleukin-2 receptor alpha/CD25.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

A revival of bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

pUR 250 allows rapid chemical sequencing of both DNA strands of its inserts

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Towards high-throughput single cell/clone cultivation and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Isolation of scFvs to in vitro produced extracellular domains of EGFR family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

Automated, high-resolution cellular retention and uptake studies in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBA20090096

21 January 2018

Identifiers

DOI

10.1042/BA20090096

1 reference

16 September 2017

1 reference